Site search
2811 results for '' found
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymp
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymp
/
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gu
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gu
/
Double-Blind Randomised Investigation of Bazedoxifene and conjugated estrogen for Depression in Menopausal Women (ACTRN12620001015932)
Double-Blind Randomised Investigation of Bazedoxifene and conjugated estrogen for Depression in Menopausal Women (ACTRN12620001015932)
/
Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)
Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)
/
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
/
A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)
A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)
/
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
/
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
/
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Availabl
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Availabl
/
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
/